Abstract
Background/Objectives: The relationship between pre-existing diabetes mellitus (DM) and acute pancreatitis (AP) severity has not been established. We assessed the impact of pre-existing DM on AP severity in an international, prospectively ascertained registry. Methods: APPRENTICE registry prospectively enrolled 1543 AP patients from 22 centers across 4 continents (8 US, 6 Europe, 5 Latin America, 3 India) between 2015 and 2018, and collected detailed clinical information. Pre-existing DM was defined a diagnosis of DM prior to AP admission. The primary outcome was AP severity defined by the Revised Atlanta Classification (RAC). Secondary outcomes were development of systemic inflammatory response syndrome (SIRS) or intensive care unit (ICU) admission. Results: Pre-existing DM was present in 270 (17.5%) AP patients, of whom 252 (93.3%) had type 2 DM. Patients with pre-existing DM were significantly (p < 0.05) older (55.8 ± 16 vs. 48.3 ± 18.7 years), more likely to be overweight (BMI 29.5 ± 7 vs. 27.2 ± 6.2), have hypertriglyceridemia as the etiology (15% vs. 2%) and prior AP (33 vs. 24%). Mild, moderate, and severe AP were noted in 66%, 23%, and 11% of patients, respectively. On multivariable analysis, pre-existing DM did not significantly impact AP severity assessed by the RAC (moderate-severe vs. mild AP, OR = 0.86, 95% CI 0.63–1.18; severe vs. mild-moderate AP, OR = 1.05, 95% CI, 0.67–1.63), development of SIRS, or the need for ICU admission. No interaction was noted between DM status and continent. Conclusion: About one in 5 patients with AP have pre-existing DM. Once confounding risk factors are considered, pre-existing DM per se is not a risk factor for severe AP.
Original language | English |
---|---|
Pages (from-to) | 85-91 |
Number of pages | 7 |
Journal | Pancreatology |
Volume | 22 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2022 |
Bibliographical note
Publisher Copyright:© 2021
Funding
Research reported in this publication was supported under award numbers - U01 DK108306 (DY) by the National Cancer Institute (NCI) and NIDDK - U01DK108306 and U01DK127377 (DY), the Department of Defense – DoD PR 182623 (DY), U01DK127388 (GIP, DLC), U01DK127400 (VKS), U01DK127377 (FGST), and NIH T32CA186873 (PP) training grant in cancer epidemiology and prevention. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Defense. All the other authors have no disclosures.
Funders | Funder number |
---|---|
FGST | |
National Institutes of Health (NIH) | |
U.S. Department of Defense | PR 182623 |
U.S. Department of Defense | |
National Childhood Cancer Registry – National Cancer Institute | T32CA186873 |
National Childhood Cancer Registry – National Cancer Institute | |
National Institute of Diabetes and Digestive and Kidney Diseases | U01DK108306, U01DK127377, U01DK127388, U01DK127400 |
National Institute of Diabetes and Digestive and Kidney Diseases |
Keywords
- Diabetes
- Etiology
- Hospitalization
- Mortality
- Pancreatitis
- Prevalence
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Hepatology